NVAX Q1 2021 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena

NVAXNovavax, Inc.

$2B

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$447M+13143.4% YoY

Gross Profit

$447M100.0% margin

Operating Income

-$209M-46.6% margin

Net Income

-$223M-49.8% margin

EPS (Diluted)

$-3.05

QoQ Revenue Growth

+59.9%

Cash Flow

Operating Cash Flow

$663M

Free Cash Flow

$649M

Stock-Based Comp.

$53M

Balance Sheet

Total Assets

$2.6B

Total Liabilities

$1.6B

Stockholders' Equity

$1.0B

Cash & Equivalents

$2.0B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$447M	$3M	+13143.4%
Gross Profit	$447M	$3M	+13143.4%
Operating Income	-$209M	-$23M	-811.2%
Net Income	-$223M	-$26M	-761.1%

Revenue Segments

Government Contract

$383M86%

Grant

$65M14%